SIRPA, BTN3A1, and TDO2 in osteosarcoma: a prognostic triad with therapeutic implications from integrated genomic and pharmacogenomic data
Abstract The limited understanding of the prognostic implications of immune checkpoint molecules in osteosarcoma (OS) poses significant challenges for improving patient outcomes. There is a gap in the identification of reliable biomarkers that can predict treatment response and prognosis in OS patie...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | Journal of Orthopaedic Surgery and Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13018-025-06171-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849234717243604992 |
|---|---|
| author | Han-jing Zhang Zhi-Jun Yang Wen Huang Dan Chen Jie Xiang Wen-kang Chen |
| author_facet | Han-jing Zhang Zhi-Jun Yang Wen Huang Dan Chen Jie Xiang Wen-kang Chen |
| author_sort | Han-jing Zhang |
| collection | DOAJ |
| description | Abstract The limited understanding of the prognostic implications of immune checkpoint molecules in osteosarcoma (OS) poses significant challenges for improving patient outcomes. There is a gap in the identification of reliable biomarkers that can predict treatment response and prognosis in OS patients. This study focused on investigating the prognostic value of immune checkpoints, specifically BTN3A1, SIRPA, and TDO2, using data from the TARGET database and clinical follow-up data from our hospitals. By conducting univariate Cox regression and least absolute shrinkage and selection operator (LASSO) analyses, we identified these immune checkpoints as significant prognostic indicators. A three-immune-checkpoint genetic prognostic risk model was developed, which demonstrated different prognostic implications across different clinical subgroups. Drug sensitivity analysis revealed that BTN3A1, SIRPA, and TDO2 were correlated with the efficacy of several antineoplastic agents, including hydroxyurea and docetaxel. Validation in our clinical cohort highlighted the significant prognostic value of SIRPA, suggesting its potential as a target for immunotherapy. These findings established a framework for using immune checkpoints as prognostic biomarkers, highlighting their important role in enhancing personalized treatment strategies for OS patients. |
| format | Article |
| id | doaj-art-b6bea19041664d7eb7d81eae76e247cc |
| institution | Kabale University |
| issn | 1749-799X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Orthopaedic Surgery and Research |
| spelling | doaj-art-b6bea19041664d7eb7d81eae76e247cc2025-08-20T04:03:03ZengBMCJournal of Orthopaedic Surgery and Research1749-799X2025-08-0120111710.1186/s13018-025-06171-7SIRPA, BTN3A1, and TDO2 in osteosarcoma: a prognostic triad with therapeutic implications from integrated genomic and pharmacogenomic dataHan-jing Zhang0Zhi-Jun Yang1Wen Huang2Dan Chen3Jie Xiang4Wen-kang Chen5Department of Orthopaedics, The First Affiliated Hospital, Hengyang Medical School, University of South ChinaDepartment of Orthopaedics, The First Affiliated Hospital, Hengyang Medical School, University of South ChinaDepartment of Orthopaedics, The First Affiliated Hospital, Hengyang Medical School, University of South ChinaDepartment of Orthopaedics, The First Affiliated Hospital, Hengyang Medical School, University of South ChinaDepartment of Orthopaedics, The First Affiliated Hospital, Hengyang Medical School, University of South ChinaDepartment of Orthopaedics, The First Affiliated Hospital, Hengyang Medical School, University of South ChinaAbstract The limited understanding of the prognostic implications of immune checkpoint molecules in osteosarcoma (OS) poses significant challenges for improving patient outcomes. There is a gap in the identification of reliable biomarkers that can predict treatment response and prognosis in OS patients. This study focused on investigating the prognostic value of immune checkpoints, specifically BTN3A1, SIRPA, and TDO2, using data from the TARGET database and clinical follow-up data from our hospitals. By conducting univariate Cox regression and least absolute shrinkage and selection operator (LASSO) analyses, we identified these immune checkpoints as significant prognostic indicators. A three-immune-checkpoint genetic prognostic risk model was developed, which demonstrated different prognostic implications across different clinical subgroups. Drug sensitivity analysis revealed that BTN3A1, SIRPA, and TDO2 were correlated with the efficacy of several antineoplastic agents, including hydroxyurea and docetaxel. Validation in our clinical cohort highlighted the significant prognostic value of SIRPA, suggesting its potential as a target for immunotherapy. These findings established a framework for using immune checkpoints as prognostic biomarkers, highlighting their important role in enhancing personalized treatment strategies for OS patients.https://doi.org/10.1186/s13018-025-06171-7OsteosarcomaImmune checkpointsPrognosisImmune therapySIRPA |
| spellingShingle | Han-jing Zhang Zhi-Jun Yang Wen Huang Dan Chen Jie Xiang Wen-kang Chen SIRPA, BTN3A1, and TDO2 in osteosarcoma: a prognostic triad with therapeutic implications from integrated genomic and pharmacogenomic data Journal of Orthopaedic Surgery and Research Osteosarcoma Immune checkpoints Prognosis Immune therapy SIRPA |
| title | SIRPA, BTN3A1, and TDO2 in osteosarcoma: a prognostic triad with therapeutic implications from integrated genomic and pharmacogenomic data |
| title_full | SIRPA, BTN3A1, and TDO2 in osteosarcoma: a prognostic triad with therapeutic implications from integrated genomic and pharmacogenomic data |
| title_fullStr | SIRPA, BTN3A1, and TDO2 in osteosarcoma: a prognostic triad with therapeutic implications from integrated genomic and pharmacogenomic data |
| title_full_unstemmed | SIRPA, BTN3A1, and TDO2 in osteosarcoma: a prognostic triad with therapeutic implications from integrated genomic and pharmacogenomic data |
| title_short | SIRPA, BTN3A1, and TDO2 in osteosarcoma: a prognostic triad with therapeutic implications from integrated genomic and pharmacogenomic data |
| title_sort | sirpa btn3a1 and tdo2 in osteosarcoma a prognostic triad with therapeutic implications from integrated genomic and pharmacogenomic data |
| topic | Osteosarcoma Immune checkpoints Prognosis Immune therapy SIRPA |
| url | https://doi.org/10.1186/s13018-025-06171-7 |
| work_keys_str_mv | AT hanjingzhang sirpabtn3a1andtdo2inosteosarcomaaprognostictriadwiththerapeuticimplicationsfromintegratedgenomicandpharmacogenomicdata AT zhijunyang sirpabtn3a1andtdo2inosteosarcomaaprognostictriadwiththerapeuticimplicationsfromintegratedgenomicandpharmacogenomicdata AT wenhuang sirpabtn3a1andtdo2inosteosarcomaaprognostictriadwiththerapeuticimplicationsfromintegratedgenomicandpharmacogenomicdata AT danchen sirpabtn3a1andtdo2inosteosarcomaaprognostictriadwiththerapeuticimplicationsfromintegratedgenomicandpharmacogenomicdata AT jiexiang sirpabtn3a1andtdo2inosteosarcomaaprognostictriadwiththerapeuticimplicationsfromintegratedgenomicandpharmacogenomicdata AT wenkangchen sirpabtn3a1andtdo2inosteosarcomaaprognostictriadwiththerapeuticimplicationsfromintegratedgenomicandpharmacogenomicdata |